DE60116371T3 - Variante des modifizierten vaccinia ankara virus - Google Patents
Variante des modifizierten vaccinia ankara virus Download PDFInfo
- Publication number
- DE60116371T3 DE60116371T3 DE60116371.0T DE60116371T DE60116371T3 DE 60116371 T3 DE60116371 T3 DE 60116371T3 DE 60116371 T DE60116371 T DE 60116371T DE 60116371 T3 DE60116371 T3 DE 60116371T3
- Authority
- DE
- Germany
- Prior art keywords
- mva
- derivative
- virus
- vaccine
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A61K39/285—Vaccinia virus or variola virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pulmonology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200001764 | 2000-11-23 | ||
DK200001764 | 2000-11-23 | ||
EP01991753.3A EP1335987B2 (en) | 2000-11-23 | 2001-11-22 | Modified vaccinia ankara virus variant |
PCT/EP2001/013628 WO2002042480A2 (en) | 2000-11-23 | 2001-11-22 | Modified vaccinia ankara virus variant |
Publications (3)
Publication Number | Publication Date |
---|---|
DE60116371D1 DE60116371D1 (de) | 2006-02-02 |
DE60116371T2 DE60116371T2 (de) | 2006-09-07 |
DE60116371T3 true DE60116371T3 (de) | 2016-11-17 |
Family
ID=8159864
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE20122302U Expired - Lifetime DE20122302U1 (de) | 2000-11-23 | 2001-11-22 | Variante des Modifizierten Vaccinia-Ankara-Virus |
DE60116371.0T Expired - Lifetime DE60116371T3 (de) | 2000-11-23 | 2001-11-22 | Variante des modifizierten vaccinia ankara virus |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE20122302U Expired - Lifetime DE20122302U1 (de) | 2000-11-23 | 2001-11-22 | Variante des Modifizierten Vaccinia-Ankara-Virus |
Country Status (30)
Country | Link |
---|---|
US (11) | US6913752B2 (no) |
EP (4) | EP2204452A1 (no) |
JP (1) | JP4421188B2 (no) |
KR (3) | KR100830295B1 (no) |
CN (2) | CN100537773C (no) |
AT (1) | ATE314483T2 (no) |
AU (2) | AU3163902A (no) |
BE (1) | BE2013C065I2 (no) |
BR (1) | BRPI0115533B8 (no) |
CA (1) | CA2421151C (no) |
CY (2) | CY1105594T1 (no) |
CZ (1) | CZ295808B6 (no) |
DE (2) | DE20122302U1 (no) |
DK (1) | DK1335987T4 (no) |
EE (1) | EE05680B1 (no) |
ES (1) | ES2256323T5 (no) |
FR (1) | FR13C0070I2 (no) |
HK (1) | HK1059453A1 (no) |
HU (2) | HU230198B1 (no) |
IL (2) | IL154712A0 (no) |
LU (1) | LU92311I2 (no) |
MX (1) | MXPA03002513A (no) |
NO (1) | NO337867B1 (no) |
NZ (1) | NZ524661A (no) |
PL (1) | PL212047B1 (no) |
PT (1) | PT1335987E (no) |
RU (1) | RU2290438C2 (no) |
SI (1) | SI1335987T2 (no) |
UA (1) | UA76731C2 (no) |
WO (1) | WO2002042480A2 (no) |
Families Citing this family (150)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7628980B2 (en) | 2000-11-23 | 2009-12-08 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
US7445924B2 (en) | 2000-11-23 | 2008-11-04 | Bavarian Nordic A/S | Modified Vaccinia Ankara virus variant and cultivation method |
EE05680B1 (et) | 2000-11-23 | 2013-10-15 | Bavarian Nordic A/S | Muundatud vaktsiiniaviirus, selle valmistamine ja kasutamine, seda sisaldav farmatseutiline kompositsioon ning vaktsiin |
US7097842B2 (en) | 2000-11-23 | 2006-08-29 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
UA82466C2 (uk) * | 2001-07-18 | 2008-04-25 | Бавариан Нордика А/С | Спосіб посилення ампліфікації хордопоксвірусу |
CA2466413C (en) * | 2001-12-04 | 2014-11-04 | Bavarian Nordic A/S | Flavivirus ns1 subunit vaccine |
KR101028937B1 (ko) * | 2002-04-19 | 2011-04-12 | 버베리안 노딕 에이/에스 | 신생아의 백신접종용 변형 백시니아 바이러스 안카라 |
NZ536500A (en) * | 2002-05-16 | 2008-01-31 | Bavarian Nordic As | Expression of genes in modified vaccinia virus ankara by using the cowpox ATI promoter |
PL218318B1 (pl) | 2002-05-16 | 2014-11-28 | Bavarian Nordic As | Rekombinowany wirus krowianki Ankara (MVA), zawierająca go komórka, szczepionka lub kompozycja farmaceutyczna, sposób lub zestaw do jego otrzymywania, sekwencja DNA zawierająca genom tego wirusa oraz sposób wykrywania tego wirusa lub komórek nim zainfekowanych |
US7501127B2 (en) | 2002-05-16 | 2009-03-10 | Bavarian Nordic A/S | Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara |
EA009008B1 (ru) | 2002-09-05 | 2007-10-26 | Бавариан Нордик А/С | Способ амплификации вируса оспы |
EP1845164B1 (en) * | 2003-11-24 | 2010-06-16 | Bavarian Nordic A/S | Promoters for expression in modified vaccinia virus ankara |
ES2357772T3 (es) * | 2004-06-14 | 2011-04-29 | Ishihara Sangyo Kaisha, Ltd. | Composición liofilizada de envuelta viral inactivada con actividad de fusión de membrana. |
CN1295339C (zh) * | 2005-01-11 | 2007-01-17 | 武汉大学 | 减毒痘苗病毒天坛株载体及制备方法和应用 |
LT1855720T (lt) * | 2005-02-23 | 2017-01-10 | Bavarian Nordic A/S | Modifikuoto raupų viruso panaudojimas greitam imuniteto sužadinimui prieš raupų virusą arba kitus infekcinius agentus |
US20090269365A1 (en) * | 2005-04-20 | 2009-10-29 | University Of Washington | Immunogenic vaccinia peptides and methods of using same |
KR100717279B1 (ko) * | 2005-08-08 | 2007-05-15 | 삼성전자주식회사 | 마스크롬 소자 및 그 형성 방법 |
US7913477B2 (en) * | 2006-01-27 | 2011-03-29 | William Anthony Harper | Insert registration in packets |
EP1826264A1 (en) * | 2006-02-24 | 2007-08-29 | Deutsches Primatenzentrum GmbH | Primate model for orthopox virus infections |
EP1835031A1 (en) | 2006-03-14 | 2007-09-19 | Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe | Use of a recombinant modified vaccinia virus Ankara (MVA) for the treatment of type I hypersensitivity in a living animal including humans |
EP2029756B1 (en) * | 2006-06-20 | 2016-11-09 | Transgene S.A. | Process for producing poxviruses and poxvirus compositions |
CN101472610A (zh) | 2006-06-20 | 2009-07-01 | 特朗斯吉有限公司 | 重组病毒疫苗 |
CA2662730A1 (en) * | 2006-09-08 | 2008-03-13 | Bavarian Nordic A/S | Phenotypic and genotypic differences of mva strains |
DK2073837T3 (da) * | 2006-10-06 | 2014-09-29 | Bavarian Nordic Inc | Rekombinant modificeret vaccinia-ankara-virus, der koder for et her-2-antigen, i kombination med en taxan til anvendelse til behandling af cancer |
US8268327B2 (en) | 2007-04-27 | 2012-09-18 | Bavarian Nordic A/S | Immediate protection against pathogens via MVA |
US8003364B2 (en) * | 2007-05-14 | 2011-08-23 | Bavarian Nordic A/S | Purification of vaccinia viruses using hydrophobic interaction chromatography |
JP2010526546A (ja) | 2007-05-14 | 2010-08-05 | バヴァリアン・ノルディック・アクティーゼルスカブ | ワクシニアウイルス系及び組換えワクシニアウイルス系ワクチンの精製 |
AU2008312444B2 (en) * | 2007-10-18 | 2014-02-06 | Bavarian Nordic A/S | Use of MVA to treat prostate cancer |
KR100970449B1 (ko) * | 2007-12-21 | 2010-07-16 | (주)이지아이 | 안전성을 갖는 어린이 놀이터용 고무 바닥재 및 설치방법 |
WO2009152969A1 (en) * | 2008-06-20 | 2009-12-23 | Bavarian Nordic A/S | Recombinant modified vaccinia virus measles vaccine |
MX2011007386A (es) | 2009-01-20 | 2011-08-03 | Transgene Sa | Icam-1 soluble como un biomarcador para la prediccion de una respuesta terapeutica. |
US8613936B2 (en) | 2009-03-13 | 2013-12-24 | Bavarian Nordic A/S | Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements |
US8394385B2 (en) * | 2009-03-13 | 2013-03-12 | Bavarian Nordic A/S | Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines |
SG2014014021A (en) | 2009-03-24 | 2014-07-30 | Transgene Sa | Biomarker for monitoring patients |
NZ594896A (en) | 2009-04-17 | 2013-07-26 | Transgene Sa | Biomarker for monitoring patients |
SG176619A1 (en) | 2009-07-10 | 2012-01-30 | Transgene Sa | Biomarker for selecting patients and related methods |
JP2013507107A (ja) | 2009-10-08 | 2013-03-04 | バヴァリアン・ノルディック・アクティーゼルスカブ | Hivに対するヒトにおける広範なt細胞応答の生成 |
US9011874B2 (en) * | 2009-11-20 | 2015-04-21 | Takeda Vaccines, Inc. | Compositions, methods and uses for poxvirus elements in vaccine constructs |
DK2529010T3 (en) | 2010-01-28 | 2017-07-24 | Bavarian Nordic As | MUTANTS OF VACCINIAVIRUS CONTAINING THE MAIN GENOMIC DELETIONS OF VAT |
EP2550362B1 (en) | 2010-03-25 | 2017-01-04 | Oregon Health&Science University | Cmv glycoproteins and recombinant vectors |
AU2011281982B2 (en) | 2010-07-20 | 2015-12-17 | Bavarian Nordic A/S | Method for harvesting expression products |
WO2012018856A2 (en) * | 2010-08-02 | 2012-02-09 | Virxsys Corporation | Hiv vaccine therapy with concomitant antiviral monotherapy |
NZ608143A (en) | 2010-10-15 | 2015-02-27 | Bavarian Nordic As | Recombinant modified vaccinia virus ankara (mva) influenza vaccine |
RS57397B8 (sr) | 2011-06-10 | 2020-01-31 | Univ Oregon Health & Science | Cmv glikoproteini i rekombinantni vektori |
PL2739293T3 (pl) | 2011-08-05 | 2020-11-16 | Sillajen Biotherapeutics, Inc. | Sposoby i kompozycje wytwarzania wirusa krowianki |
EP2568289A3 (en) | 2011-09-12 | 2013-04-03 | International AIDS Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
EP2788021B1 (en) | 2011-12-09 | 2017-01-18 | Bavarian Nordic A/S | Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c |
EP2620446A1 (en) | 2012-01-27 | 2013-07-31 | Laboratorios Del Dr. Esteve, S.A. | Immunogens for HIV vaccination |
US10111946B2 (en) | 2012-06-22 | 2018-10-30 | Bavarian Nordic A/S | Poxviral vectors for low antibody response after a first priming immunization |
EP2679596B1 (en) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 env glycoprotein variant |
CA2878800A1 (en) | 2012-07-10 | 2014-01-16 | Transgene Sa | Mycobacterial antigen vaccine |
WO2014009433A1 (en) | 2012-07-10 | 2014-01-16 | Transgene Sa | Mycobacterium resuscitation promoting factor for use as adjuvant |
KR102264852B1 (ko) | 2012-08-01 | 2021-06-14 | 버베리안 노딕 에이/에스 | 재조합 변형된 백시니아 바이러스 앙카라(ankara) (mva) 호흡기 신시티알 바이러스(rsv) 백신 |
EP2892549A1 (en) | 2012-09-04 | 2015-07-15 | Bavarian Nordic A/S | Methods and compositions for enhancing vaccine immune responses |
WO2014043535A1 (en) | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions for the treatment of cancer |
CA2888367A1 (en) | 2012-10-19 | 2014-04-24 | Bavarian Nordic, Inc. | Methods and compositions for the treatment of cancer |
SI2912183T1 (sl) | 2012-10-28 | 2020-07-31 | Bavarian Nordic A/S | Promotor Pr13.5 za odzive robustne T-celice in protiteles |
CN105101993A (zh) * | 2013-03-15 | 2015-11-25 | 巴法里安诺迪克有限公司 | 单次高剂量的mva在新生儿和婴儿中诱导保护性免疫反应 |
EP2848937A1 (en) | 2013-09-05 | 2015-03-18 | International Aids Vaccine Initiative | Methods of identifying novel HIV-1 immunogens |
US10058604B2 (en) | 2013-10-07 | 2018-08-28 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
JP6788500B2 (ja) | 2013-10-23 | 2020-11-25 | アメリカ合衆国 | Muc1−c癌タンパク質のhla−a24アゴニストエピトープ及び組成物及び使用方法 |
WO2015077717A1 (en) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status |
NZ759538A (en) | 2013-11-28 | 2022-10-28 | Bavarian Nordic As | Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors |
US11725237B2 (en) | 2013-12-05 | 2023-08-15 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
CN106456724A (zh) | 2013-12-20 | 2017-02-22 | 博德研究所 | 使用新抗原疫苗的联合疗法 |
WO2015104380A1 (en) | 2014-01-09 | 2015-07-16 | Transgene Sa | Fusion of heterooligomeric mycobacterial antigens |
DK3142689T3 (da) | 2014-05-13 | 2021-02-15 | Bavarian Nordic As | Kombinationsbehandling til behandling af cancer med en koppevirus, som udtrykker et tumorantigen, og et monoklonalt antistof mod tim-3 |
MX2016016533A (es) | 2014-06-13 | 2017-05-01 | Glaxosmithkline Biologicals Sa | Combinaciones inmunogenas. |
IL250743B (en) | 2014-09-03 | 2022-08-01 | Bavarian Nordic As | Methods and compositions for inducing protective immunity against filovirus infection |
BR112017004202A2 (pt) | 2014-09-03 | 2019-09-03 | Bavarian Nordic As | composições para intensificar respostas imunes e seus usos |
BR112017005917A2 (pt) | 2014-09-26 | 2017-12-12 | Beth Israel Deaconess Medical Ct Inc | processos e composições para indução de imunidade protetora contra infecção com o vírus da imunodeficiência humana |
KR101623498B1 (ko) | 2014-10-16 | 2016-05-24 | 대한민국 | 약독화 백시니아 바이러스주 kvac103 |
KR101645642B1 (ko) | 2014-10-16 | 2016-08-11 | 대한민국 | Kvac103 유래의 재조합 백시니아 바이러스 |
SG11201702997YA (en) | 2014-11-04 | 2017-05-30 | Janssen Vaccines & Prevention Bv | Therapeutic hpv16 vaccines |
US10975442B2 (en) | 2014-12-19 | 2021-04-13 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
WO2016100977A1 (en) | 2014-12-19 | 2016-06-23 | The Broad Institute Inc. | Methods for profiling the t-cel- receptor repertoire |
AU2016229408A1 (en) | 2015-02-25 | 2017-09-14 | Memorial Sloan-Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
EP3069730A3 (en) | 2015-03-20 | 2017-03-15 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
WO2016168862A1 (en) | 2015-04-17 | 2016-10-20 | Memorial Sloan-Kettering Cancer Center | Use of mva or mvadeltae3l as immunotherapeutic agents against solid tumors |
EP3297660A2 (en) | 2015-05-20 | 2018-03-28 | The Broad Institute Inc. | Shared neoantigens |
TWI750122B (zh) | 2015-06-09 | 2021-12-21 | 美商博德研究所有限公司 | 用於贅瘤疫苗之調配物及其製備方法 |
EA201890042A1 (ru) * | 2015-06-15 | 2018-05-31 | Бавариан Нордик А/С | Вакцина против вируса ящура (вя) на основе рекомбинантного модифицированного вируса осповакцины анкара (mva) |
US9925258B2 (en) | 2015-10-02 | 2018-03-27 | International Aids Vaccine Initiative | Replication-competent VSV-HIV Env vaccines |
FR3042121A1 (fr) | 2015-10-08 | 2017-04-14 | Jean-Marc Limacher | Composition anti-tumorale |
CN106591361A (zh) * | 2015-10-20 | 2017-04-26 | 钱文斌 | 一种重组痘溶瘤病毒及其构建方法和应用 |
TWI792091B (zh) | 2015-12-15 | 2023-02-11 | 荷蘭商傑森疫苗防護公司 | 人類免疫缺陷病毒抗原、載體、組成物、及其使用方法 |
CA3009928A1 (en) | 2016-01-29 | 2017-08-03 | Bavarian Nordic A/S | Recombinant modified vaccinia virus ankara (mva) equine encephalitis virus vaccine |
CN109152815B (zh) | 2016-02-25 | 2022-10-18 | 纪念斯隆凯特琳癌症中心 | 用于癌症免疫治疗的具有胸苷激酶缺失和具有或不具有人flt3l或gm-csf表达的复制型减毒痘苗病毒 |
IL261321B2 (en) | 2016-02-25 | 2023-12-01 | Memorial Sloan Kettering Cancer Center | Recombinant MVA or MVADELE3L expressing human FLT3L and their use as immunotherapeutic agents against solid tumors |
CA3020426A1 (en) | 2016-04-13 | 2017-10-19 | Synthetic Genomics, Inc. | Recombinant arterivirus replicon systems and uses thereof |
WO2017184590A1 (en) | 2016-04-18 | 2017-10-26 | The Broad Institute Inc. | Improved hla epitope prediction |
CA3021341A1 (en) | 2016-05-02 | 2017-11-09 | Janssen Vaccine & Prevention B.V. | Therapeutic hpv vaccine combinations |
CN109219448B (zh) | 2016-06-16 | 2022-09-20 | 扬森疫苗与预防公司 | Hiv疫苗配制品 |
US10925956B2 (en) | 2016-07-15 | 2021-02-23 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against a marburg virus infection |
US10307477B2 (en) | 2016-09-02 | 2019-06-04 | Janssen Vaccines & Prevention B.V. | Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
JP7178344B2 (ja) | 2016-09-15 | 2022-11-25 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | 三量体安定化hivエンベロープタンパク質変異 |
WO2018060368A2 (en) | 2016-09-28 | 2018-04-05 | Bavarian Nordic A/S | Compositions and methods for enhancing the stability of transgenes in poxviruses |
CA3040264A1 (en) | 2016-10-17 | 2018-04-26 | Synthetic Genomics, Inc. | Recombinant virus replicon systems and uses thereof |
CA3042703A1 (en) | 2016-11-07 | 2018-05-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Development of agonist epitopes of the human papillomavirus |
US11845939B2 (en) | 2016-12-05 | 2023-12-19 | Janssen Pharmaceuticals, Inc. | Compositions and methods for enhancing gene expression |
EP3574116A1 (en) | 2017-01-24 | 2019-12-04 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
US11173204B2 (en) | 2017-04-06 | 2021-11-16 | Janssen Vaccines & Prevention B.V. | MVA-BN and Ad26.ZEBOV or Ad26.filo prime-boost regimen |
US11242509B2 (en) | 2017-05-12 | 2022-02-08 | Memorial Sloan Kettering Cancer Center | Vaccinia virus mutants useful for cancer immunotherapy |
JP2020519666A (ja) | 2017-05-15 | 2020-07-02 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | 安定性のウイルス含有組成物 |
EP3624845A1 (en) | 2017-05-15 | 2020-03-25 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
KR20200015759A (ko) | 2017-06-15 | 2020-02-12 | 얀센 백신스 앤드 프리벤션 비.브이. | Hiv 항원을 인코딩하는 폭스바이러스 벡터, 및 그 사용 방법 |
KR20200031655A (ko) | 2017-07-19 | 2020-03-24 | 얀센 백신스 앤드 프리벤션 비.브이. | 삼량체를 안정화하는 hiv 엔벨로프 단백질 돌연변이 |
WO2019018724A1 (en) | 2017-07-21 | 2019-01-24 | Janssen Vaccines & Prevention B.V. | METHODS FOR SAFE INDUCTION OF MULTICLADED CROSS-IMMUNITY AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN HUMAN BEINGS |
MX2020001856A (es) | 2017-08-24 | 2020-07-13 | Bavarian Nordic As | Terapia de combinacion para tratar el cancer con administracion intravenosa de un virus vaccinia ankara modificado (mva) recombinante y un anticuerpo. |
US20190083620A1 (en) | 2017-09-18 | 2019-03-21 | Janssen Vaccines & Prevention B.V. | Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
EA202091513A1 (ru) | 2017-12-19 | 2020-09-09 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Вакцины против вируса гепатита b (hbv) и их применение |
EA202091517A1 (ru) | 2017-12-19 | 2020-11-03 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Способы и устройство для доставки вакцин против вируса гепатита b (hbv) |
MX2020006471A (es) | 2017-12-19 | 2020-09-22 | Janssen Sciences Ireland Unlimited Co | Metodos y composiciones para inducir una respuesta inmune contra el virus de hepatitis b (hbv). |
US11020476B2 (en) | 2017-12-19 | 2021-06-01 | Janssen Sciences Ireland Unlimited Company | Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV) |
EP3728291A1 (en) | 2017-12-20 | 2020-10-28 | GlaxoSmithKline Biologicals S.A. | Epstein-barr virus antigen constructs |
US11083786B2 (en) | 2018-01-19 | 2021-08-10 | Janssen Pharmaceuticals, Inc. | Induce and enhance immune responses using recombinant replicon systems |
US20220001001A1 (en) * | 2018-07-13 | 2022-01-06 | University Of Georgia Research Foundation | Broadly reactive immunogens of dengue virus, compositions, and methods of use thereof |
US20210187100A1 (en) | 2018-09-06 | 2021-06-24 | Bavarian Nordic A/S | Storage Improved Poxvirus Compositions |
WO2020072700A1 (en) | 2018-10-02 | 2020-04-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
CA3113818A1 (en) | 2018-10-05 | 2020-04-09 | Bavarian Nordic A/S | Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist |
EP3880694A1 (en) | 2018-11-14 | 2021-09-22 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Tp5, a peptide inhibitor of aberrant and hyperactive cdk5/p25 as treatment for cancer |
AU2019385665A1 (en) | 2018-11-20 | 2021-05-27 | Bavarian Nordic A/S | Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant MVA encoding 4-1BBL (CD137L) and/or CD40l |
WO2020131586A2 (en) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Methods for identifying neoantigens |
TW202043256A (zh) | 2019-01-10 | 2020-12-01 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
WO2020237052A1 (en) | 2019-05-22 | 2020-11-26 | Janssen Vaccines & Prevention B.V. | Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
US20220305120A1 (en) | 2019-06-11 | 2022-09-29 | Glaxosmithkline Biologicals Sa | Mucosal vaccine formulations |
WO2021094984A1 (en) | 2019-11-14 | 2021-05-20 | Aelix Therapeutics, S.L. | Dosage regimens for vaccines |
WO2021099572A1 (en) | 2019-11-20 | 2021-05-27 | Bavarian Nordic A/S | Medical uses of 4-1bbl adjuvanted recombinant modified vaccinia virus ankara (mva) |
WO2021099586A1 (en) | 2019-11-20 | 2021-05-27 | Bavarian Nordic A/S | Recombinant mva viruses for intratumoral and/or intravenous administration for treating cancer |
WO2021150713A2 (en) | 2020-01-21 | 2021-07-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human immunogenic epitopes of h, k, and e human endogenous retroviruses (hervs) |
US20230287067A1 (en) | 2020-01-21 | 2023-09-14 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Human immunogenic epitopes of hemo and hhla2 human endogenous retroviruses (hervs) |
CN115243717A (zh) | 2020-03-12 | 2022-10-25 | 巴法里安诺迪克有限公司 | 改善痘病毒稳定性的组合物 |
CA3181431A1 (en) | 2020-06-10 | 2021-12-16 | Jurgen Hausmann | A recombinant modified vaccinia virus ankara (mva) vaccine against coronavirus disease |
WO2021260065A1 (en) | 2020-06-24 | 2021-12-30 | Consejo Superior De Investigaciones Científicas (Csic) | Mva-based vaccine against covid-19 expressing sars-cov-2 antigens |
EP3928789A1 (en) | 2020-06-24 | 2021-12-29 | Consejo Superior de Investigaciones Científicas (CSIC) | Mva-based vaccine against covid-19 expressing sars-cov-2 antigens |
WO2022008613A1 (en) | 2020-07-08 | 2022-01-13 | Janssen Sciences Ireland Unlimited Company | Rna replicon vaccines against hbv |
WO2022084333A1 (en) | 2020-10-20 | 2022-04-28 | Janssen Vaccines & Prevention B.V. | Hiv vaccine regimens |
EP4358999A1 (en) | 2021-06-23 | 2024-05-01 | Consejo Superior De Investigaciones Científicas | Mva-based vaccine expressing a prefusion-stabilized sars-cov-2 s protein |
EP4108257A1 (en) | 2021-06-23 | 2022-12-28 | Consejo Superior De Investigaciones Científicas | Mva-based vaccine against covid-19 expressing a prefusion-stabilized sars-cov-2 s protein |
KR20240051214A (ko) | 2021-09-03 | 2024-04-19 | 버베리안 노딕 에이/에스 | 변형 백시니아 바이러스 앙카라(mva)에 의한 세포독성 전이유전자 발현의 하향조절을 위한 마이크로rna의 활용 |
WO2023118508A1 (en) | 2021-12-23 | 2023-06-29 | Bavarian Nordic A/S | Recombinant mva viruses for intraperitoneal administration for treating cancer |
WO2023118563A1 (en) | 2021-12-23 | 2023-06-29 | Bavarian Nordic A/S | Therapy for modulating immune response with recombinant mva encoding il-12 |
WO2023198815A1 (en) | 2022-04-14 | 2023-10-19 | Janssen Vaccines & Prevention B.V. | Sequential administration of adenoviruses |
WO2024003239A1 (en) | 2022-06-29 | 2024-01-04 | Bavarian Nordic A/S | RECOMBINANT MODIFIED saRNA (VRP) AND VACCINIA VIRUS ANKARA (MVA) PRIME-BOOST REGIMEN |
WO2024003238A1 (en) | 2022-06-29 | 2024-01-04 | Bavarian Nordic A/S | Epstein-barr-virus vaccine |
WO2024003346A1 (en) | 2022-06-30 | 2024-01-04 | Bavarian Nordic A/S | Mammalian cell line for the production of modified vaccinia virus ankara (mva) |
WO2024015892A1 (en) | 2022-07-13 | 2024-01-18 | The Broad Institute, Inc. | Hla-ii immunopeptidome methods and systems for antigen discovery |
EP4316514A1 (en) | 2022-08-03 | 2024-02-07 | Consejo Superior de Investigaciones Científicas (CSIC) | Mva-based vectors and their use as vaccine against sars-cov-2 |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4072565A (en) * | 1974-11-04 | 1978-02-07 | The Dow Chemical Company | Production of viruses in tissue culture without use of serum |
US3914408A (en) * | 1973-10-12 | 1975-10-21 | Univ Nebraska | Vaccine for neonatal calf diarrhea |
DE2714665A1 (de) * | 1977-04-01 | 1978-10-05 | Mayr Anton | Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung |
US5155020A (en) * | 1989-03-08 | 1992-10-13 | Health Research Inc. | Recombinant poxvirus host range selection system |
US5338683A (en) | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
GB8322414D0 (en) * | 1983-08-19 | 1983-09-21 | Szelke M | Renin inhibitors |
AU613583B2 (en) | 1986-08-22 | 1991-08-08 | Transgene S.A. | Proteins and the method for preparing them, DNA sequences, antibodies and their application, poxviruses, transformed or infected cells, pharmaceutical compositions which are useful in the prevention of schistosomiasis and application by way of an agent possessing glutathione s-transferase activity |
FR2603040B1 (fr) | 1986-08-22 | 1990-01-26 | Transgene Sa | Proteine, sequence d'adn, poxvirus, cellules et leur procede de culture, ainsi que les compositions pharmaceutiques les contenant, utiles dans la prevention de la schistosomose |
DE3743298A1 (de) | 1987-12-19 | 1989-06-29 | Wilkinson Sword Gmbh | Rasierapparat und verfahren zur herstellung einer flaeche geringen reibungswiderstands an einem rasierapparat |
CA1341245C (en) | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
US6248333B1 (en) * | 1990-04-04 | 2001-06-19 | Health Research Inc. | Isolated nucleic acid sequence of equine herpesvirus type 1 glycoprotein D (EHV-1 gD) |
EP0550638A4 (en) | 1990-09-25 | 1993-12-08 | Smithkline Beecham Corporation | Medium for culture of mammalian cells |
JP3602530B2 (ja) * | 1991-03-07 | 2004-12-15 | ヴァイロジェネティクス コーポレイション | 遺伝子操作したワクチン菌株 |
US5843456A (en) * | 1991-03-07 | 1998-12-01 | Virogenetics Corporation | Alvac poxvirus-rabies compositions and combination compositions and uses |
US5403582A (en) | 1993-01-21 | 1995-04-04 | Nippon Zeon Co., Ltd. | Vaccine comprising fowlpox virus recombinants expressing the envelope glycoprotein of an avian reticuloendotheliosis retrovirus |
US5405772A (en) | 1993-06-18 | 1995-04-11 | Amgen Inc. | Medium for long-term proliferation and development of cells |
US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
US5490794A (en) * | 1993-11-05 | 1996-02-13 | Sumitomo Wiring Systems, Ltd. | Branch joint box |
US6190655B1 (en) | 1993-12-03 | 2001-02-20 | Immunex Corporation | Methods of using Flt-3 ligand for exogenous gene transfer |
DE4405841C1 (de) * | 1994-02-23 | 1995-01-05 | Mayr Anton Prof Dr Med Vet Dr | Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
ES2243937T3 (es) * | 1994-04-29 | 2005-12-01 | Baxter Healthcare S.A. | Poxvirus recombinados en regiones esenciales con la ayuda de polinucleotidos extraños. |
CN1180843C (zh) * | 1994-07-27 | 2004-12-22 | 昆士兰医学研究所 | 多表位疫苗 |
US5676950A (en) * | 1994-10-28 | 1997-10-14 | University Of Florida | Enterically administered recombinant poxvirus vaccines |
US5756341A (en) | 1994-11-10 | 1998-05-26 | Immuno Ag | Method for controlling the infectivity of viruses |
US5753489A (en) | 1994-11-10 | 1998-05-19 | Immuno Ag | Method for producing viruses and vaccines in serum-free culture |
US5566011A (en) * | 1994-12-08 | 1996-10-15 | Luncent Technologies Inc. | Antiflector black matrix having successively a chromium oxide layer, a molybdenum layer and a second chromium oxide layer |
UA68327C2 (en) † | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
JP2000517290A (ja) | 1996-02-21 | 2000-12-26 | リスジーウィックス,ジュリアナ | 保護的及び治療的な遺伝子免疫化のための方法及び組成物 |
WO1998004680A1 (en) | 1996-07-26 | 1998-02-05 | University Of Manitoba | Serum-free medium for growth of anchorage-dependant mammalian cells |
EP0951555A2 (en) † | 1996-09-24 | 1999-10-27 | Bavarian Nordic Research Institute A/S | Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines |
WO1998017283A1 (en) | 1996-10-25 | 1998-04-30 | The Wistar Institute Of Anatomy & Biology | Method of vaccinating infants against infections |
US6204250B1 (en) * | 1996-11-22 | 2001-03-20 | The Mount Sinai Medical Center Of The City Of New York | Immunization of infants |
US20030138454A1 (en) * | 1997-06-09 | 2003-07-24 | Oxxon Pharmaccines, Ltd. | Vaccination method |
GB9711957D0 (en) * | 1997-06-09 | 1997-08-06 | Isis Innovation | Methods and reagents for vaccination |
GB0023203D0 (en) | 2000-09-21 | 2000-11-01 | Isis Innovation | Vaccination method |
DE19729279A1 (de) † | 1997-07-09 | 1999-01-14 | Peter Hildebrandt | Urologisches Implantat, insbesondere Gefäßwandstütze für den Urinaltrakt |
WO1999007869A1 (en) † | 1997-08-05 | 1999-02-18 | University Of Florida | Live recombinant vaccine comprising inefficiently or non-replicating virus |
US6667176B1 (en) * | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
DE69839970D1 (de) | 1998-11-10 | 2008-10-16 | Univ Rochester | Methoden zu herstellung von genbanken |
EP2042598A1 (en) | 1998-11-18 | 2009-04-01 | Oxford Biomedica (UK) Limited | 5T4 tumour-associated antigen for use in tumour immunotherapy |
GB2370571B (en) | 1998-11-18 | 2003-05-07 | Oxford Biomedica Ltd | A modified 5t4 antigen |
US6173813B1 (en) | 1998-12-23 | 2001-01-16 | Otis Elevator Company | Electronic control for an elevator braking system |
US6497883B1 (en) | 1999-06-10 | 2002-12-24 | Merial | Porcine circovirus recombinant poxvirus vaccine |
CN1311871C (zh) * | 2000-03-02 | 2007-04-25 | 爱莫里大学 | Dna表达载体及其应用方法 |
CA2397675C (en) | 2000-03-14 | 2012-11-13 | Anton Mayr | Altered strain of the modified vaccinia virus ankara (mva) |
KR100341030B1 (ko) | 2000-03-16 | 2002-06-20 | 유태욱 | 캡션 데이터와 음성 데이터의 재생방법 및 이를 이용한 디스플레이장치 |
JP2003533989A (ja) | 2000-05-24 | 2003-11-18 | メリアル | ブタ生殖・呼吸症候群ウィルス(prrsv)の組換えポックスウィルスワクチン |
JP5037775B2 (ja) * | 2000-07-11 | 2012-10-03 | アイキュリス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフト | 抗ウイルス薬および癌に対する医薬の製造のためのパラポックスウイルスovisの使用 |
US6733993B2 (en) * | 2000-09-15 | 2004-05-11 | Merck & Co., Inc. | Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications |
EE05680B1 (et) * | 2000-11-23 | 2013-10-15 | Bavarian Nordic A/S | Muundatud vaktsiiniaviirus, selle valmistamine ja kasutamine, seda sisaldav farmatseutiline kompositsioon ning vaktsiin |
US7445924B2 (en) * | 2000-11-23 | 2008-11-04 | Bavarian Nordic A/S | Modified Vaccinia Ankara virus variant and cultivation method |
US7628980B2 (en) * | 2000-11-23 | 2009-12-08 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
US7097842B2 (en) * | 2000-11-23 | 2006-08-29 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
UA82466C2 (uk) * | 2001-07-18 | 2008-04-25 | Бавариан Нордика А/С | Спосіб посилення ампліфікації хордопоксвірусу |
CA2466413C (en) * | 2001-12-04 | 2014-11-04 | Bavarian Nordic A/S | Flavivirus ns1 subunit vaccine |
UA77735C2 (en) | 2001-12-20 | 2007-01-15 | Bavarian Nordic As | Method for recovery of poxviruses from infected cells |
WO2003078640A2 (en) | 2002-03-15 | 2003-09-25 | Baxter International Inc. | Recombinant drug-sensitive vaccinia virus as smallpox vaccine |
KR101028937B1 (ko) * | 2002-04-19 | 2011-04-12 | 버베리안 노딕 에이/에스 | 신생아의 백신접종용 변형 백시니아 바이러스 안카라 |
PL218318B1 (pl) * | 2002-05-16 | 2014-11-28 | Bavarian Nordic As | Rekombinowany wirus krowianki Ankara (MVA), zawierająca go komórka, szczepionka lub kompozycja farmaceutyczna, sposób lub zestaw do jego otrzymywania, sekwencja DNA zawierająca genom tego wirusa oraz sposób wykrywania tego wirusa lub komórek nim zainfekowanych |
NZ536500A (en) * | 2002-05-16 | 2008-01-31 | Bavarian Nordic As | Expression of genes in modified vaccinia virus ankara by using the cowpox ATI promoter |
EA009008B1 (ru) * | 2002-09-05 | 2007-10-26 | Бавариан Нордик А/С | Способ амплификации вируса оспы |
CN1717488A (zh) * | 2002-11-25 | 2006-01-04 | 巴法里安诺迪克有限公司 | 包含至少两个牛痘ati启动子的重组痘病毒 |
US6976752B2 (en) * | 2003-10-28 | 2005-12-20 | Lexmark International, Inc. | Ink jet printer with resistance compensation circuit |
EP1845164B1 (en) * | 2003-11-24 | 2010-06-16 | Bavarian Nordic A/S | Promoters for expression in modified vaccinia virus ankara |
EP1586330A1 (en) * | 2004-04-16 | 2005-10-19 | Georg-August-Universität Göttingen | Vaccination against malignant melanoma |
US8354093B2 (en) * | 2004-10-15 | 2013-01-15 | Washington University | Cell permeable nanoconjugates of shell-crosslinked knedel (SCK) and peptide nucleic acids (“PNAs”) with uniquely expressed or over-expressed mRNA targeting sequences for early diagnosis and therapy of cancer |
EP1835031A1 (en) | 2006-03-14 | 2007-09-19 | Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe | Use of a recombinant modified vaccinia virus Ankara (MVA) for the treatment of type I hypersensitivity in a living animal including humans |
DK2073837T3 (da) * | 2006-10-06 | 2014-09-29 | Bavarian Nordic Inc | Rekombinant modificeret vaccinia-ankara-virus, der koder for et her-2-antigen, i kombination med en taxan til anvendelse til behandling af cancer |
EP1925318A1 (en) | 2006-11-20 | 2008-05-28 | Paul-Ehrlich-Institut | Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu |
US8268327B2 (en) * | 2007-04-27 | 2012-09-18 | Bavarian Nordic A/S | Immediate protection against pathogens via MVA |
AU2008312444B2 (en) * | 2007-10-18 | 2014-02-06 | Bavarian Nordic A/S | Use of MVA to treat prostate cancer |
-
2001
- 2001-11-22 EE EEP200300173A patent/EE05680B1/xx unknown
- 2001-11-22 CN CNB018194109A patent/CN100537773C/zh not_active Expired - Lifetime
- 2001-11-22 CN CN200910151102A patent/CN101676389A/zh active Pending
- 2001-11-22 AT AT01991753T patent/ATE314483T2/de active
- 2001-11-22 DE DE20122302U patent/DE20122302U1/de not_active Expired - Lifetime
- 2001-11-22 EP EP10158053A patent/EP2204452A1/en not_active Withdrawn
- 2001-11-22 KR KR1020037006970A patent/KR100830295B1/ko active IP Right Grant
- 2001-11-22 DE DE60116371.0T patent/DE60116371T3/de not_active Expired - Lifetime
- 2001-11-22 MX MXPA03002513A patent/MXPA03002513A/es active IP Right Grant
- 2001-11-22 AU AU3163902A patent/AU3163902A/xx active Pending
- 2001-11-22 SI SI200130512T patent/SI1335987T2/sl unknown
- 2001-11-22 KR KR1020097010451A patent/KR20090057335A/ko not_active Application Discontinuation
- 2001-11-22 BR BRPI0115533A patent/BRPI0115533B8/pt not_active IP Right Cessation
- 2001-11-22 RU RU2003118436/13A patent/RU2290438C2/ru active
- 2001-11-22 DK DK01991753.3T patent/DK1335987T4/en active
- 2001-11-22 EP EP01991753.3A patent/EP1335987B2/en not_active Expired - Lifetime
- 2001-11-22 ES ES01991753.3T patent/ES2256323T5/es not_active Expired - Lifetime
- 2001-11-22 WO PCT/EP2001/013628 patent/WO2002042480A2/en active Application Filing
- 2001-11-22 KR KR1020087007423A patent/KR100910297B1/ko active IP Right Grant
- 2001-11-22 HU HU0400685A patent/HU230198B1/hu active Protection Beyond IP Right Term
- 2001-11-22 AU AU2002231639A patent/AU2002231639B2/en not_active Expired
- 2001-11-22 NZ NZ524661A patent/NZ524661A/en not_active IP Right Cessation
- 2001-11-22 PT PT01991753T patent/PT1335987E/pt unknown
- 2001-11-22 CA CA2421151A patent/CA2421151C/en not_active Expired - Lifetime
- 2001-11-22 EP EP10158051A patent/EP2202315A1/en not_active Withdrawn
- 2001-11-22 EP EP05017694A patent/EP1598425A1/en not_active Withdrawn
- 2001-11-22 JP JP2002545184A patent/JP4421188B2/ja not_active Expired - Lifetime
- 2001-11-22 CZ CZ20031366A patent/CZ295808B6/cs not_active IP Right Cessation
- 2001-11-22 IL IL15471201A patent/IL154712A0/xx unknown
- 2001-11-22 PL PL361459A patent/PL212047B1/pl unknown
- 2001-11-22 UA UA2003054618A patent/UA76731C2/uk unknown
-
2003
- 2003-03-03 IL IL154712A patent/IL154712A/en active IP Right Grant
- 2003-05-16 US US10/439,439 patent/US6913752B2/en not_active Expired - Lifetime
- 2003-05-16 US US10/440,073 patent/US7189536B2/en not_active Expired - Lifetime
- 2003-05-16 US US10/439,953 patent/US6761893B2/en not_active Expired - Lifetime
- 2003-05-21 NO NO20032309A patent/NO337867B1/no not_active IP Right Cessation
-
2004
- 2004-03-31 HK HK04102348.1A patent/HK1059453A1/xx not_active IP Right Cessation
-
2005
- 2005-08-05 US US11/198,557 patent/US7384644B2/en not_active Expired - Lifetime
-
2006
- 2006-03-27 CY CY20061100421T patent/CY1105594T1/el unknown
- 2006-08-23 US US11/508,797 patent/US7335364B2/en not_active Expired - Lifetime
-
2007
- 2007-10-26 US US11/977,808 patent/US7923017B2/en not_active Expired - Fee Related
- 2007-12-04 US US11/999,127 patent/US7459270B2/en not_active Expired - Lifetime
-
2009
- 2009-05-22 US US12/471,144 patent/US7939086B2/en not_active Expired - Lifetime
-
2011
- 2011-03-22 US US13/053,361 patent/US8268325B2/en not_active Expired - Lifetime
- 2011-03-22 US US13/053,450 patent/US8268329B2/en not_active Expired - Lifetime
-
2012
- 2012-08-17 US US13/588,217 patent/US20120328650A1/en not_active Abandoned
-
2013
- 2013-11-20 LU LU92311C patent/LU92311I2/fr unknown
- 2013-11-21 BE BE2013C065C patent/BE2013C065I2/fr unknown
- 2013-12-13 FR FR13C0070C patent/FR13C0070I2/fr active Active
- 2013-12-23 CY CY2013048C patent/CY2013048I1/el unknown
-
2016
- 2016-02-29 HU HUS1600010C patent/HUS1600010I1/hu unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60116371T3 (de) | Variante des modifizierten vaccinia ankara virus | |
DE60303218T2 (de) | Intergene regionen als insertionsstellen im genom von modifiziertem vaccinia virus ankara (mva) | |
DE60314541T2 (de) | Mindestens zwei ati promotoren enthaltendes rekombinantes pockenvirus | |
DE602004009743T2 (de) | Promotoren zur Expression in modifiziertem Vaccinia Virus Ankara | |
DE60302848T2 (de) | Expression von genen im modifizierten vaccinia virus ankara durch verwendung eines cowpox ati promoter |